CompletedPhase 1NCT01268358

Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Studying Alpha-mannosidosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zymenex A/S
Principal Investigator: Allan M. Lund, MD
Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark
Intervention: Lamazym(drug)
Enrollment: 10 enrolled
Eligibility: 5-20 years · All sexes
Timeline: 2010 – 2011

Collaborators

European Commission

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01268358 on ClinicalTrials.gov

Other trials for Alpha-mannosidosis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06184503
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
Chiesi Farmaceutici S.p.A.

See all trials for Alpha-mannosidosis →

← Back to all trials